Engineered exosomes for targeted delivery

Abstract

The present disclosure provides for an engineered exosome or extracellular vesicle, wherein the engineered exosome or extracellular vesicle is substantially devoid of endogenous nucleic acids and can comprise at least one targeting moiety and/or at least one payload or cargo. The payload or cargo can be a diagnostic agent or a therapeutic agent such as exogenous nucleic acids and/or a CRISPR/Cas system for gene editing. The engineered exosomes can be used to treat disease.

Dependencies are inferred from the claim text.